Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Rund 40 Mio. USD Staatsaufträge bis Juni 2029 gebucht: Jetzt zählt die Marge!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
SX

WKN: A0M4YV | ISIN: CNE100000411 | Ticker: XIN
Frankfurt
19.11.26 | 08:06
0,550 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
SHANDONG XINHUA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
SHANDONG XINHUA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,5500,61516:30

Aktuelle News zur SHANDONG XINHUA PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.11.SHANDONG XINHUA (00719): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS-
SHANDONG XINHUA PHARMACEUTICAL Aktie jetzt für 0€ handeln
10.11.SHANDONG XINHUA (00719): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING AND CHANGE OF THE CHAIRMAN OF COMPANY-
06.11.SHANDONG XINHUA (00719): OVERSEAS REGULATORY ANNOUNCEMENT-ANNOUNCEMENT ON KETOROLAC TROMETHAMINE INJECTION HAVING OBTAINED DRUG REGISTRATION CERTIFICATE-
28.10.Shandong Xinhua Pharmaceutical Co Ltd Nine Months Profit Falls1
28.10.SHANDONG XINHUA (00719): UNAUDITED QUARTERLY RESULTS ANNOUNCEMENT FOR THE NINE MONTHS ENDED 30 SEPTEMBER 20261
20.10.SHANDONG XINHUA Nimodipine Tablets Pass Generic Drug Consistency Evaluation4
19.10.SHANDONG XINHUA (00719): OVERSEAS REGULATORY ANNOUNCEMENT-ANNOUNCEMENT ON NIMODIPINE TABLETS HAVING PASSED THE GENERICS CONSISTENCY EVALUATION1
14.10.SHANDONG XINHUA (00719): ANNOUNCEMENT NOTICE OF BOARD MEETING2
09.10.SHANDONG XINHUA (00719): PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR-
08.10.SHANDONG XINHUA (00719): OVERSEAS REGULATORY ANNOUNCEMENT-ANNOUNCEMENT ON SACUBITRIL VALSARTAN SODIUM TABLETS HAVING OBTAINED DRUG REGISTRATION CERTIFICATE1
22.09.SHANDONG XINHUA (00719): 2026 INTERIM REPORT2
18.09.SHANDONG XINHUA (00719): OVERSEAS REGULATORY ANNOUNCEMENT-ANNOUNCEMENT ON MAGNESIUM SULFATE, SODIUM SULFATE AND POTASSIUM SULFATE CONCENTRATE ORAL SOLUTION ...-
18.09.SHANDONG XINHUA (00719): OVERSEAS REGULATORY ANNOUNCEMENT-ANNOUNCEMENT ON LEVOCARNITINE ORAL SOLUTION HAVING OBTAINED DRUG REGISTRATION CERTIFICATE-
18.09.SHANDONG XINHUA (00719): OVERSEAS REGULATORY ANNOUNCEMENT-ANNOUNCEMENT ON DONEPEZIL HYDROCHLORIDE ORALLY DISINTEGRATING TABLETS OF SUBSIDIARY HAVING OBTAINED ...-
31.08.SHANDONG XINHUA (00719): OVERSEAS REGULATORY ANNOUNCEMENT-ANNOUNCEMENT ON AZITHROMYCIN TABLETS HAVING PASSED THE GENERICS CONSISTENCY EVALUATION2
28.08.SHANDONG XINHUA (00719): OVERSEAS REGULATORY ANNOUNCEMENT-ANNOUNCEMENT ON DAPOXETINE HYDROCHLORIDE TABLETS HAVING OBTAINED DRUG REGISTRATION CERTIFICATE1
25.08.Shandong Xinhua Pharmaceutical Co Ltd H1 Profit Falls1
25.08.SHANDONG XINHUA (00719): 2026 INTERIM RESULTS ANNOUNCEMENT-
21.08.SHANDONG XINHUA (00719): OVERSEAS REGULATORY ANNOUNCEMENT-ANNOUNCEMENT ON DAPAGLIFLOZIN TABLETS HAVING OBTAINED DRUG REGISTRATION CERTIFICATE1
11.08.SHANDONG XINHUA (00719): ANNOUNCEMENT NOTICE OF BOARD MEETING-
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1